Literature DB >> 15723656

STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1.

Hajime Nakatani1, Michiya Kobayashi, Toufeng Jin, Takahiro Taguchi, Takeki Sugimoto, Takumi Nakano, Shinichi Hamada, Keijiro Araki.   

Abstract

The gastrointestinal stromal tumor cell line, GIST-T1, has a heterogenic 57-base pair deletion in exon 11 of the c-kit mutation, and the c-KIT protein in the GIST-T1 cells constitutively activated. We report that STI571 (Glivec; Novartis, Basel, Switzerland), a specific inhibitor of c-KIT, inhibits the clustering of c-KIT at the cell membrane of the GIST-T1 cells. Furthermore, STI571 prevents the interaction between c-KIT and the molecular chaperone, heat shock protein 90 (Hsp90). Geldanamycin, an inhibitor of Hsp90, also prevents interaction between c-KIT and Hsp90, and inhibits tyrosine phosphorylation of c-KIT. Our results indicate that c-KIT molecules are assembled on the cell surface of the GIST-T1 cells, and that the interaction between c-KIT and Hsp90 plays an important role in c-KIT activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15723656     DOI: 10.1111/j.1349-7006.2005.00018.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  12 in total

Review 1.  Targeted therapy for cancer: the gastrointestinal stromal tumor model.

Authors:  Vinod P Balachandran; Ronald P Dematteo
Journal:  Surg Oncol Clin N Am       Date:  2013-07-24       Impact factor: 3.495

Review 2.  Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.

Authors:  Mrinal M Gounder; Robert G Maki
Journal:  Cancer Chemother Pharmacol       Date:  2010-11-30       Impact factor: 3.333

Review 3.  Recent advances in therapy for gastrointestinal stromal tumors.

Authors:  Robert G Maki
Journal:  Curr Oncol Rep       Date:  2007-05       Impact factor: 5.075

4.  The role of oncogenes in gastrointestinal cancer.

Authors:  Emmanouil P Pappou; Nita Ahuja
Journal:  Gastrointest Cancer Res       Date:  2010-11

5.  A novel anti-c-Kit antibody-drug conjugate to treat wild-type and activating-mutant c-Kit-positive tumors.

Authors:  Jin-Ock Kim; Kwang-Hyeok Kim; Eun Ji Baek; Bomi Park; Min Kyung So; Byoung Joon Ko; Han-Jik Ko; Sang Gyu Park
Journal:  Mol Oncol       Date:  2021-08-29       Impact factor: 6.603

6.  Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.

Authors:  Thomas Mühlenberg; Yixiang Zhang; Andrew J Wagner; Florian Grabellus; James Bradner; Georg Taeger; Hauke Lang; Takahiro Taguchi; Martin Schuler; Jonathan A Fletcher; Sebastian Bauer
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

7.  Gastrointestinal Stromal Tumors (GIST) and Their Management.

Authors:  Robert G Maki
Journal:  Gastrointest Cancer Res       Date:  2007

Review 8.  New therapeutic approaches for advanced gastrointestinal stromal tumors.

Authors:  Neeta Somaiah; Margaret von Mehren
Journal:  Hematol Oncol Clin North Am       Date:  2009-02       Impact factor: 3.722

9.  p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.

Authors:  Joern Henze; Thomas Mühlenberg; Susanne Simon; Florian Grabellus; Brian Rubin; Georg Taeger; Martin Schuler; Juergen Treckmann; Maria Debiec-Rychter; Takahiro Taguchi; Jonathan A Fletcher; Sebastian Bauer
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

10.  ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system.

Authors:  Sigrun Polier; Rahul S Samant; Paul A Clarke; Paul Workman; Chrisostomos Prodromou; Laurence H Pearl
Journal:  Nat Chem Biol       Date:  2013-03-17       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.